Elevation Oncology Inc. (ELEV)
Elevation Oncology Statistics
Share Statistics
Elevation Oncology has 59.12M shares outstanding. The number of shares has increased by 8.2% in one year.
| Shares Outstanding | 59.12M |
| Shares Change (YoY) | 8.2% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 67.63% |
| Shares Floating | 52.06M |
| Failed to Deliver (FTD) Shares | 5.54K |
| FTD / Avg. Volume | 0.21% |
Short Selling Information
The latest short interest is 8.94M, so 15.13% of the outstanding shares have been sold short.
| Short Interest | 8.94M |
| Short % of Shares Out | 15.13% |
| Short % of Float | 17.19% |
| Short Ratio (days to cover) | 2.22 |
Valuation Ratios
The PE ratio is -0.72 and the forward PE ratio is -0.73. Elevation Oncology's PEG ratio is 0.02.
| PE Ratio | -0.72 |
| Forward PE | -0.73 |
| PS Ratio | 0 |
| Forward PS | 0.1 |
| PB Ratio | 0.54 |
| P/FCF Ratio | -0.89 |
| PEG Ratio | 0.02 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Elevation Oncology.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 21.21, with a Debt / Equity ratio of 0.52.
| Current Ratio | 21.21 |
| Quick Ratio | 21.21 |
| Debt / Equity | 0.52 |
| Debt / EBITDA | -0.7 |
| Debt / FCF | -0.86 |
| Interest Coverage | -37.16 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1.31M |
| Employee Count | 34 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 43K |
| Effective Tax Rate | -0.1% |
Stock Price Statistics
The stock price has increased by -95.13% in the last 52 weeks. The beta is 1.38, so Elevation Oncology's price volatility has been higher than the market average.
| Beta | 1.38 |
| 52-Week Price Change | -95.13% |
| 50-Day Moving Average | 0.53 |
| 200-Day Moving Average | 0.99 |
| Relative Strength Index (RSI) | 22.8 |
| Average Volume (20 Days) | 2.63M |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -44.7M |
| Net Income | -44.48M |
| EBITDA | -44.7M |
| EBIT | -43.24M |
| Earnings Per Share (EPS) | -0.78 |
Balance Sheet
The company has 49.46M in cash and 31.13M in debt, giving a net cash position of 18.33M.
| Cash & Cash Equivalents | 49.46M |
| Total Debt | 31.13M |
| Net Cash | 18.33M |
| Retained Earnings | -240.46M |
| Total Assets | 95.63M |
| Working Capital | 90.26M |
Cash Flow
In the last 12 months, operating cash flow was -36.36M and capital expenditures 0, giving a free cash flow of -36.36M.
| Operating Cash Flow | -36.36M |
| Capital Expenditures | 0 |
| Free Cash Flow | -36.36M |
| FCF Per Share | -0.63 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ELEV does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for ELEV is $5, which is 1900% higher than the current price. The consensus rating is "Buy".
| Price Target | $5 |
| Price Target Difference | 1900% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
Scores
| Altman Z-Score | -3.54 |
| Piotroski F-Score | 1 |